Ilaria Stura Selected Research

nintedanib

1/2019

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ilaria Stura Research Topics

Disease

2	Neoplasms (Cancer) 02/2018 - 01/2018
1	Iron Overload 02/2024
1	Extranodal Extension 10/2023
1	Syringomyelia (Morvan's Disease) 04/2023
1	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2022
1	Alzheimer Disease (Alzheimer's Disease) 09/2022
1	COVID-19 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019
1	Necrosis 02/2018
1	Prostatic Neoplasms (Prostate Cancer) 01/2016

Drug/Important Bio-Agent (IBA)

1	Capsules (Microcapsules)IBA 10/2023
1	IronIBA 09/2022
1	Immunoglobulin G (IgG)IBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2021
1	AntibodiesIBA 01/2021
1	nintedanibIBA 01/2019
1	Docetaxel (Taxotere)FDA Link 01/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2018
1	Oxygen (Dioxygen)IBA 02/2018
1	ChitosanIBA 02/2018
1	Contrast MediaIBA 01/2018

Therapy/Procedure

1	Therapeutics 02/2024
1	Decompression 04/2023
1	Prostatectomy (Retropubic Prostatectomy) 01/2016